Tags

Type your tag names separated by a space and hit enter

Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2.
Signal Transduct Target Ther. 2020 Sep 22; 5(1):212.ST

Abstract

The outbreaks of severe acute respiratory syndrome (SARS) and Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV and SARS-CoV-2, respectively, have posed severe threats to global public health and the economy. Treatment and prevention of these viral diseases call for the research and development of human neutralizing monoclonal antibodies (NMAbs). Scientists have screened neutralizing antibodies using the virus receptor-binding domain (RBD) as an antigen, indicating that RBD contains multiple conformational neutralizing epitopes, which are the main structural domains for inducing neutralizing antibodies and T-cell immune responses. This review summarizes the structure and function of RBD and RBD-specific NMAbs against SARS-CoV and SARS-CoV-2 currently under development.

Links

PMC Free PDF

Authors+Show Affiliations

Yu F
College of Life Sciences, Hebei Agricultural University, Baoding, China.
Xiang R
College of Life Sciences, Hebei Agricultural University, Baoding, China.
Deng X
College of Life Sciences, Hebei Agricultural University, Baoding, China.
Wang L
Research Center of Chinese Jujube, Hebei Agricultural University, Baoding, China.
Yu Z
College of Life Sciences, Hebei Agricultural University, Baoding, China.
Tian S
College of Life Sciences, Hebei Agricultural University, Baoding, China.
Liang R
College of Life Sciences, Hebei Agricultural University, Baoding, China.
Li Y
College of Life Sciences, Hebei Agricultural University, Baoding, China.
Ying T
Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai, China. tlying@fudan.edu.cn.
Jiang S
Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai, China. shibojiang@fudan.edu.cn.

MeSH

Angiotensin-Converting Enzyme 2Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralBetacoronavirusCOVID-19Coronavirus InfectionsCross ReactionsEpitopesHumansModels, MolecularPandemicsPeptidyl-Dipeptidase APneumonia, ViralProtein BindingProtein Structure, SecondaryReceptors, VirusSevere acute respiratory syndrome-related coronavirusSARS-CoV-2Severe Acute Respiratory SyndromeSpike Glycoprotein, CoronavirusVirion

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

32963228

Citation

Yu, Fei, et al. "Receptor-binding Domain-specific Human Neutralizing Monoclonal Antibodies Against SARS-CoV and SARS-CoV-2." Signal Transduction and Targeted Therapy, vol. 5, no. 1, 2020, p. 212.
Yu F, Xiang R, Deng X, et al. Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. Signal Transduct Target Ther. 2020;5(1):212.
Yu, F., Xiang, R., Deng, X., Wang, L., Yu, Z., Tian, S., Liang, R., Li, Y., Ying, T., & Jiang, S. (2020). Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. Signal Transduction and Targeted Therapy, 5(1), 212. https://doi.org/10.1038/s41392-020-00318-0
Yu F, et al. Receptor-binding Domain-specific Human Neutralizing Monoclonal Antibodies Against SARS-CoV and SARS-CoV-2. Signal Transduct Target Ther. 2020 Sep 22;5(1):212. PubMed PMID: 32963228.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. AU - Yu,Fei, AU - Xiang,Rong, AU - Deng,Xiaoqian, AU - Wang,Lili, AU - Yu,Zhengsen, AU - Tian,Shijun, AU - Liang,Ruiying, AU - Li,Yanbai, AU - Ying,Tianlei, AU - Jiang,Shibo, Y1 - 2020/09/22/ PY - 2020/7/9/received PY - 2020/9/3/accepted PY - 2020/8/28/revised PY - 2020/9/23/entrez PY - 2020/9/24/pubmed PY - 2020/10/7/medline SP - 212 EP - 212 JF - Signal transduction and targeted therapy JO - Signal Transduct Target Ther VL - 5 IS - 1 N2 - The outbreaks of severe acute respiratory syndrome (SARS) and Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV and SARS-CoV-2, respectively, have posed severe threats to global public health and the economy. Treatment and prevention of these viral diseases call for the research and development of human neutralizing monoclonal antibodies (NMAbs). Scientists have screened neutralizing antibodies using the virus receptor-binding domain (RBD) as an antigen, indicating that RBD contains multiple conformational neutralizing epitopes, which are the main structural domains for inducing neutralizing antibodies and T-cell immune responses. This review summarizes the structure and function of RBD and RBD-specific NMAbs against SARS-CoV and SARS-CoV-2 currently under development. SN - 2059-3635 UR - https://www.unboundmedicine.com/medline/citation/32963228/Receptor_binding_domain_specific_human_neutralizing_monoclonal_antibodies_against_SARS_CoV_and_SARS_CoV_2_ DB - PRIME DP - Unbound Medicine ER -